TACI antibody (PE/Dazzle™ 594)

Catalog No. ABIN2659695

Product Details anti-TACI Antibody (PE/Dazzle™ 594)

Target: TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))

Reactivity: Human

Host: Rat

Clonality: Monoclonal

Conjugate: This TACI antibody is conjugated to PE/Dazzle™ 594

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

Clone: 1A1

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for TACI

Target: TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))

Alternative Name: CD267 (TNFRSF13B Products)

Synonyms: CD267 antibody, CVID antibody, CVID2 antibody, RYZN antibody, TACI antibody, TNFRSF14B antibody, TNFRSF13B antibody, 1200009E08Rik antibody, Taci antibody, TNF receptor superfamily member 13B antibody, tumor necrosis factor receptor superfamily, member 13b antibody, TNFRSF13B antibody, Tnfrsf13b antibody

Background: TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.